PBYI

Zacks highlights four breast cancer drug stocks for Breast Cancer Awareness Month. AstraZeneca and Roche are established large-cap pharma companies with strong commercial portfolios and pipeline opportunities.

Puma Biotechnology relies on Nerlynx sales with a mid-stage pipeline candidate. Olema Oncology is a clinical-stage company dependent on its lead candidate palazestrant's phase III trial results expected in Q1 2027.

Four pharmaceutical and biotech companies are positioned in the breast cancer treatment market with varying growth prospects. AstraZeneca and Roche leverage established drug portfolios with expanding indications, Puma Biotechnology focuses on Nerlynx sales growth, while Olema Oncology awaits pivotal clinical trial results for its lead candidate palazestrant expected in Q1 2027.